Menu Search
Equities

Coloplast A/S

COLO B:CPH

Coloplast A/S

Actions
Health CareMedical Equipment and Services
  • Price (DKK)906.60
  • Today's Change-4.60 / -0.50%
  • Shares traded181.66k
  • 1 Year change+20.40%
  • Beta0.6245
Data delayed at least 15 minutes, as of Sep 19 2024 16:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform2
Hold13
Sell4
Strong Sell0

Share price forecast in DKK

The 21 analysts offering 12 month price targets for Coloplast A/S have a median target of 925.00, with a high estimate of 1,275.00 and a low estimate of 710.00. The median estimate represents a 1.51% increase from the last price of 911.20.
High39.9%1,275.00
Med1.5%925.00
Low-22.1%710.00

Dividends in DKK

In 2023, Coloplast A/S reported a dividend of 21.00 DKK, which represents a 5.00% increase over last year. The 20 analysts covering the company expect dividends of 20.21 DKK for the upcoming fiscal year, a decrease of 3.76%.
Div growth (TTM)5.00%
More ▼

Earnings history & estimates in DKK

On Aug 20, 2024, Coloplast A/S reported 3rd quarter 2024 earnings of 5.66 per share.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate-1.26%
Coloplast A/S reported annual 2023 earnings of 22.20 per share on Nov 09, 2023.
Average growth rate+3.33%
More ▼

Revenue history & estimates in DKK

Coloplast A/S had 3rd quarter 2024 revenues of 6.89bn. This bettered the 6.82bn consensus of the 11 analysts covering the company. This was 12.78% above the prior year's 3rd quarter results.
Average growth rate+3.07%
Coloplast A/S had revenues for the full year 2023 of 24.50bn. This was 8.51% above the prior year's results.
Average growth rate+8.22%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.